In summary, the current data support the pharmacological action mode that AZ628 and BP-1-102 combination inhibits RAS-mutant lung cancer cells by markedly abrogating MEK/ERK signaling pathway activation (Figure 6). Here, MAP2K7 is linked to lung cancer.